Group 1 - Shanghai Yunyi Technology Co., Ltd. has been established with a registered capital of 10 million yuan, focusing on technology services, development, consulting, exchange, transfer, and promotion [1] - The legal representative of the company is Zhang Weiming [1] - The company is wholly owned by Yanshan Technology [2]

上海岩山科技股份有限公司 股票交易异常波动公告 证券代码：002195 证券简称：岩山科技 公告编号：2024-047 3、公司已披露的经营情况及内外部经营环境未发生重大变化； 4、经核查，公司、控股股东及实际控制人不存在关于本公司的应披露而未 披露的重大事项，或处于筹划阶段的重大事项； 5、经核查，控股股东及实际控制人在股票交易异常波动期间不存在买卖公 司股票的情形。 三、不存在应披露而未披露信息的说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 上海岩山科技股份有限公司（以下简称"公司"或"本公司"）股票（证券 简称：岩山科技，证券代码：002195）于 2024 年 12 月 4 日、12 月 5 日连续两 个交易日内日收盘价格涨幅偏离值累计超过 20%，根据《深圳证券交易所交易 规则》的有关规定，属于股票交易异常波动情况。 二、说明关注、核实情况 针对公司股票交易异常波动，公司董事会对公司、控股股东及实际控制人就 相关事项进行了核实，现就有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未 ...

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant momentum, driven by recent developments such as Neuralink's approval for clinical trials in Canada, which is expected to enhance market sentiment and investment opportunities in the industry [1] Industry Summary - The BCI concept saw a notable rise in stock prices, with companies like Aipeng Medical reaching a 20% limit up, and others like Yanshan Technology achieving four consecutive trading gains [1] - Neuralink, a company owned by Elon Musk, has received approval from the Canadian health authorities to initiate its first clinical trial in the country, focusing on the safety of its implants and surgical robots, as well as their functionality in helping quadriplegic patients control external devices with their thoughts [1] - According to CITIC Securities, BCI is considered one of the most promising directions for new productive forces, with both domestic and international companies actively promoting the commercialization of BCI across various sectors including healthcare, industry, and entertainment [1] - Domestic policies are placing significant emphasis on the development of the BCI industry, aiming to facilitate the application and transformation of BCI technologies [1] - Companies are striving to break foreign technological monopolies and establish a fully controllable, comprehensive industrial solution [1] Company Focus - Investment opportunities are suggested in companies that are likely to benefit from overseas breakthroughs in the BCI industry, which may elevate domestic market expectations [1] - Companies that are expected to launch consumer-grade BCI products are also highlighted as potential investment targets [1] - Firms that could benefit from the practical application of BCI products are recommended for attention [1]

证券代码：002195 证券简称：岩山科技 公告编号：2024-046 上海岩山科技股份有限公司 上海岩山科技股份有限公司（以下简称"公司"或"本公司"）股票（证券 简称：岩山科技，证券代码：002195）于 2024 年 11 月 29 日、12 月 2 日、12 月 3 日连续三个交易日内日收盘价格涨幅偏离值累计超过 20%，根据《深圳证 券交易所交易规则》的有关规定，属于股票交易异常波动情况。 二、说明关注、核实情况 针对公司股票交易异常波动，公司董事会对公司、控股股东及实际控制人就 相关事项进行了核实，现就有关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共传媒报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息； 3、公司已披露的经营情况及内外部经营环境未发生重大变化； 4、经核查，公司、控股股东及实际控制人不存在关于本公司的应披露而未 披露的重大事项，或处于筹划阶段的重大事项； 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 息；公司前期披露 ...

证券代码：002195 证券简称：岩山科技 公告编号：2024-045 上海岩山科技股份有限公司 关于使用闲置自有资金进行投资理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、购买理财产品的基本情况 2024年4月16日，上海岩山科技股份有限公司（以下简称"公司"）第八届董 事会第十四次会议、第八届监事会第十次会议分别审议通过了《关于使用闲置自 有资金购买理财产品的议案》，同意公司（含控股子公司）使用不超过（含）人 民币45亿元的闲置自有资金进行委托理财，有效期自2024年5月1日起的12个月 内，在有效期内该等资金额度可滚动使用。详见公司于2024年4月18日刊登在《中 国证券报》《上海证券报》 《证券日报》《证券时报》和巨潮资讯网 （www.cninfo.com.cn）的相关公告。 | 序 | 购买主体 | 受托人 | 是否 | | | 委托理财金 | 资金 | 起始 | 预计 | 预计 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | （ ...

上海岩山科技股份有限公司 | 序号 | 修订前 | 修订后 | | --- | --- | --- | | | 第一条 为加强上海二三四五网络控股集团股份有限公司（以下简 | 第一条 为加强上海岩山科技股份有限公司（以下简称"公司"或 | | | 称"公司"）对董事、监事和高级管理人员所持本公司股份及其变 | "本公司"）对董事、监事和高级管理人员所持本公司股份及其变 | | 1 | 动的管理，明确管理程序，根据《公司法》、《证券法》、《上市 | 动的管理，明确管理程序，根据《公司法》、《证券法》、《上市 | | | 公司董事、监事和高级管理人员所持本公司股份及其变动管理规 | 公司董事、监事和高级管理人员所持本公司股份及其变动管理规 | | | 则》、深圳证券交易所（以下简称"深交所"）《深圳证券交易所 | 则》、深圳证券交易所（以下简称"深交所"）《深圳证券交易所 | 《信息披露事务管理制度》等制度修订对照表 （一）《信息披露事务管理制度》修订对照表 | 序号 | 修订前 | 修订后 | | --- | --- | --- | | 1 | 第一条 为加强对公司信息披露工作的管理，进一步提高上海二三 | 第 ...

Revenue and Profit - Revenue for the third quarter was RMB 144.55 million, an increase of 4.58% year-over-year[2] - Net profit attributable to shareholders of the listed company for the third quarter was RMB 5.38 million, a decrease of 92.27% year-over-year[2] - Operating income for the current period was 482.96 million yuan, up from 430.73 million yuan in the previous period[19] - Net profit for the current period was a loss of 17.76 million yuan, compared to a profit of 329.03 million yuan in the previous period[20] - Basic earnings per share were 0.0075 yuan, down from 0.0588 yuan in the previous period[21] - Diluted earnings per share were 0.0075 yuan, down from 0.0588 yuan in the previous period[21] Assets and Liabilities - Total assets as of the end of the third quarter were RMB 10.56 billion, an increase of 4.86% compared to the end of the previous year[2] - Total assets increased to 10.56 billion yuan from 10.07 billion yuan compared to the previous period[17][18] - Total liabilities decreased to 284.2 million yuan from 333.66 million yuan[18] - The company's equity attributable to the parent company's owners was 9.79 billion yuan, slightly up from 9.74 billion yuan[18] - Minority interest in equity increased significantly to 488.27 million yuan from 223,971.55 yuan[18] Cash Flow - Operating cash flow for the first nine months of 2024 was negative RMB 68.56 million, a decrease of 125.14% year-over-year[2] - Net cash flow from operating activities was -68,556,807.15 yuan, a significant drop from 272,746,135.60 yuan in the previous period[23] - Net cash flow from investing activities was -736,869,110.42 yuan, compared to 1,287,589,903.15 yuan in the previous period[23] - Net cash flow from financing activities was -187,393,327.40 yuan, compared to -233,761,343.29 yuan in the previous period[23] - Cash and cash equivalents at the end of the period decreased to 1,011,866,567.79 yuan from 3,797,022,639.30 yuan in the previous period[23] - Sales of goods and services generated 404,318,353.28 yuan in cash, down from 426,084,914.90 yuan in the previous period[22] - Cash received from interest and commissions was 19,737,529.76 yuan, down from 51,621,494.59 yuan in the previous period[22] - Cash paid for goods and services was 266,610,068.71 yuan, up from 215,781,642.31 yuan in the previous period[22] Expenses - Operating costs for the first nine months of 2024 increased by 44.43% to RMB 278.20 million due to higher contract fulfillment costs[5] - Sales expenses increased by 82.88% to RMB 18.13 million, mainly due to increased promotional spending[7] - Management expenses rose by 60.16% to RMB 180.67 million, primarily due to increased employee stock ownership plan costs[7] - R&D expenses surged by 184.58% to RMB 165.92 million, driven by higher R&D investments[7] - Financial expenses decreased by 74.50% to RMB -39.00 million, mainly due to reduced deposit interest income[7] - R&D expenses increased to 165.92 million yuan from 58.3 million yuan, reflecting a substantial investment in innovation[19] - Financial expenses showed a significant decrease, with a net financial income of 39 million yuan compared to a net financial income of 152.98 million yuan in the previous period[20] Investments and Subsidiaries - Inventory increased by 226.13% to RMB 25.37 million due to higher contract fulfillment costs[5] - Fixed assets increased by 74.30% to RMB 135.13 million due to the consolidation of subsidiaries[5] - Intangible assets surged by 11,800.42% to RMB 94.10 million, primarily due to the consolidation of subsidiaries[5] - Goodwill increased by 49.95% to RMB 1.44 billion, driven by the consolidation of subsidiaries[5] - The company's investment in fixed assets increased to 135.13 million yuan from 77.52 million yuan, indicating expansion in physical assets[17] - The company's wholly-owned subsidiary, Zhuhai Hengqin Yanhe Health Technology Co., Ltd., invested RMB 100 million to increase its stake in Zhejiang Pukang Biotechnology Co., Ltd., resulting in a 4.7619% ownership[14] Shareholders and Share Capital - The number of ordinary shareholders at the end of the reporting period was 222,490[9] - The company's total share capital decreased from 5,724,847,663 shares to 5,681,544,596 shares after repurchasing and canceling 43,303,067 shares, with a total repurchase amount of RMB 119,999,964.89[15] - The company's top 10 shareholders include China Industrial and Commercial Bank Co., Ltd. - GF CSI Media ETF with 39,341,000 shares, Wang Xilin with 38,669,400 shares, and Chen Yubing with 22,224,510 shares[10] - The company's top 10 shareholders' participation in margin trading includes Wang Xilin holding 30,079,700 shares through a credit securities account and Xu Lei holding 20,500,000 shares through a credit securities account[10] - The company's top 10 shareholders' proportion of total share capital includes China Agricultural Bank Co., Ltd. - CSI 500 ETF with 0.55% and 0.16% of shares lent through securities lending[11] - The company's total share capital decreased from RMB 5,724,847,663 to RMB 5,681,544,596 after the repurchase and cancellation of shares[15] Financial Position - Short-term borrowings decreased by 100% to RMB 0 as the company repaid bank loans[5] - The company's monetary funds decreased from RMB 2,012,736,688.56 to RMB 1,265,125,329.03, while trading financial assets decreased from RMB 5,298,094,148.31 to RMB 4,998,822,860.95[16] - The company's accounts receivable decreased from RMB 170,382,503.92 to RMB 149,511,062.34, and other receivables decreased from RMB 166,678,151.01 to RMB 117,773,052.34[16] - The company's prepayments increased from RMB 6,137,817.05 to RMB 16,879,979.43, and inventory increased from RMB 7,778,483.99 to RMB 25,368,112.17[16] - Investment income dropped by 58.61% to RMB 49.04 million, primarily due to reduced income from financial product redemptions[7] - Cash received from interest and commissions decreased by 61.76% to RMB 19.74 million, mainly due to reduced interest repayments from non-standard investment business[7] - Cash paid for employee compensation increased by 55.39% to RMB 242.78 million, mainly due to the addition of employees from merged subsidiaries[7] - Cash paid for taxes and fees surged by 105.12% to RMB 58.10 million, mainly due to increased income tax payments[7] - Cash received from other financing activities increased by 2,577.83% to RMB 178.11 million, mainly due to share repurchase payments[8] - Comprehensive income attributable to the parent company decreased to -18,682,701.92 yuan, compared to 336,385,484.98 yuan in the previous period[21]

第四条 在内幕信息依法披露前，内幕信息的知情人和非法获取内幕信息的 人不得公开或者泄露该信息，不得利用该信息进行内幕交易。任何单位和个人不 得非法要求信息披露义务人提供依法需要披露但尚未披露的信息。 第五条 公司的董事、监事、高级管理人员应当忠实、勤勉地履行职责，保证 披露信息的真实、准确、完整，信息披露及时、公平。 上海岩山科技股份有限公司 信息披露事务管理制度（2024 年 10 月修订） 上海岩山科技股份有限公司 信息披露事务管理制度 （2024年10月修订） 第一章 总 则 第一条 为加强对公司信息披露工作的管理，进一步提高上海岩山科技股份 有限公司（以下简称"公司"）信息披露管理水平和信息披露质量，维护公司、 投资者及其他利益相关者的合法权益，根据《中华人民共和国公司法》（以下简 称"公司法"）、《中华人民共和国证券法》（以下简称"证券法"）、《上市 公司信息披露管理办法》、《深圳证券交易所股票上市规则》、《深圳证券交易 所上市公司自律监管指引第 5 号——信息披露事务管理》等法律、法规及规范性 文件的有关规定，特制订本制度。 第二条 本制度所称信息披露是指将可能对公司股票及其衍生品种的交易价 格或 ...

证券代码：002195 证券简称：岩山科技 公告编号：2024-044 上海岩山科技股份有限公司 经审核，监事会认为：公司 2024 年第三季度报告的编制和审核程序符合法律、 行政法规、中国证监会和深圳证券交易所的规定，报告内容真实、准确、完整地反 映了公司的经营状况，不存在虚假记载、误导性陈述或重大遗漏。 《公司 2024 年第三季度报告》详见《中国证券报》《上海证券报》《证券日报》 《证券时报》及巨潮资讯网（http://www.cninfo.com.cn）。 特此公告。 第八届监事会第十三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 上海岩山科技股份有限公司（以下简称"公司"）第八届监事会第十三次会议 于 2024 年 10 月 25 日以现场及通讯表决相结合的方式在上海市浦东新区博霞路 11 号公司会议室召开，本次会议通知于 2024 年 10 月 22 日以电子邮件方式发出。 会议应参加审议监事 3 人，实际参加审议监事 3 人。本次监事会会议由监事会主席 张晓霞女士召集并主持，会议的召集、召开程序符合《公司法》和《公司章程》规 ...

上海岩山科技股份有限公司 董事、监事和高级管理人员所持本公司股份及其变动管理办法 （2024年10月修订） 第一条 为加强上海岩山科技股份有限公司（以下简称"公司"或"本公司"）对董事、监 事和高级管理人员所持本公司股份及其变动的管理，明确管理程序，根据《公司 法》、《证券法》、《上市公司董事、监事和高级管理人员所持本公司股份及其变动管理规 则》、深圳证券交易所（以下简称"深交所"）《深圳证券交易所上市公司自律监管指引 第18号——股东及董事、监事、高级管理人员减持股份》等相关法律、法规、规范性 文件的有关规定，制定本办法。 第四条 公司董事会秘书负责管理公司董事、监事和高级管理人员的身份及所 持本公司股份的数据，统一为董事、监事和高级管理人员办理个人信息的网上申 报，每季度检查董事、监事和高级管理人员买卖本公司股票的披露情况。发现违法 违规的，应当及时向中国证监会、证券交易所报告。 第五条 公司董事、监事、高级管理人员在买卖本公司股份前，应当将其买卖计划 以书面方式通知董事会秘书，董事会秘书应当核查公司信息披露及重大事项等进展情 况，如该买卖行为可能违反法律法规、深交所相关规定和公司章程等规定的，董事会 秘 ...